Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soo Yoon

Showing results (1031-1040 of 1,104) with videos related to

Pageof 111
Sort By:
Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Hemasphere|June 18, 2025
Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based studyKyung Taek Hong, Jung Yoon Choi, Hyery Kim, et al.
Clinical Transplantation|November 1, 2011
Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantationHyeon Jin Cho, Dong-Yeop Shin, Jin Hee Kim, et al.
Blood Research|January 12, 2023
Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)Christopher Chin Keong Liam, Jim Yu-Hsiang Tiao, Yee Yee Yap, et al.
Annals of Hematology|March 28, 2014
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry studySukjoong Oh, Dong Hoe Koo, Min-Jung Kwon, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
The New England Journal of Medicine|January 8, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaYael C Cohen, Hila Magen, Moshe Gatt, et al.
Blood Research|July 26, 2022
Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational studyYoung Rok Do, Yunsuk Choi, Mi Hwa Heo, et al.
Blood Research|November 21, 2021
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in KoreaJun Ho Yi, Gyeong-Won Lee, Ji Hyun Lee, et al.
Pageof 111

Showing results (1031-1040 of 1,104) with videos related to

Sort By:
Pageof 111
Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Hemasphere|June 18, 2025
Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based studyKyung Taek Hong, Jung Yoon Choi, Hyery Kim, et al.
Clinical Transplantation|November 1, 2011
Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantationHyeon Jin Cho, Dong-Yeop Shin, Jin Hee Kim, et al.
Blood Research|January 12, 2023
Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)Christopher Chin Keong Liam, Jim Yu-Hsiang Tiao, Yee Yee Yap, et al.
Annals of Hematology|March 28, 2014
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry studySukjoong Oh, Dong Hoe Koo, Min-Jung Kwon, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
The New England Journal of Medicine|January 8, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaYael C Cohen, Hila Magen, Moshe Gatt, et al.
Blood Research|July 26, 2022
Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational studyYoung Rok Do, Yunsuk Choi, Mi Hwa Heo, et al.
Blood Research|November 21, 2021
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in KoreaJun Ho Yi, Gyeong-Won Lee, Ji Hyun Lee, et al.
Pageof 111